Other
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Vertex Pharmaceuticals Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount remained flat by 0.0% to $38.60M in Q4 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionOther
CategoryEfficiency
SignalHigher is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ4 2025Feb 13, 2026
How to read this metric
Higher values indicate successful utilization of R&D tax incentives, lowering the effective tax rate.
Detailed definition
The specific dollar impact of research and development tax credits on the company's total income tax provision. This hig...
Peer comparison
Highly relevant for biotech and technology firms with heavy R&D spending.
Metric ID:
other_income_tax_reconciliation_tax_credits_researchHistorical Data
1 years
| FY'25 | |
|---|---|
| Value | $154.40M |
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount?
- Vertex Pharmaceuticals (VRTX) reported effective income tax rate reconciliation, tax credit, research, amount of $38.60M in Q4 2025.
- What does effective income tax rate reconciliation, tax credit, research, amount mean?
- Tax savings realized specifically from research and development activities.